KBC Lecture
\nTage-Erlander Professor 2011
\n\n
Paul Helquist
\nDepartment of Chemistry & Bi ochemistry\, University of Notre Dame\, Notre Dame\, Indiana
\n\n
Title:
\nFrom Simple Diene Chemistry to Therapies for R are and Neglected Diseases
\n\n
Abstract
\nIn a joint set of ventures\, the Wiest and Helquist laboratories at Notre Dam e\, specializing in computational chemistry and drug synthesis\, respectiv ely\, are supported by various funding mechanisms to reach out to investig ators in other fields and at many institutions to form multi-disciplinary collaborative teams for the purpose of drug development. Most often\, the external collaborators are at medical schools or other biomedical institut ions and have major strengths in biological or clinical studies but do not have the chemistry expertise required for drug development. These collabo rators have often identified a potential therapeutic protein target from c ellular studies\, or they have conducted compound screenings to identify i nitial hits. The next logical steps in these investigations are the design of protein binders or hit optimization\, requiring the computational and synthetic chemistry input of our laboratories. The resulting compounds are provided back to the external collaborators and other appropriate parties for more extensive biological studies. Over the past few years\, these co llaborative ties have been established with many investigators at Cornell University Weill College of Medicine\, Tufts University Medical School\, C olumbia University College of Physicians and Surgeons\, Washington Univers ity School of Medicine\, University of Texas Southwestern Medical Center\, Broad Institute\, Dana-Farber Cancer Institute\, Purdue University\, Stat e University of New York at Albany\, and Biological Sciences at Notre Dame .
\nThis presentation will place emphasis on the history of our deve lopment of synthetic methods for dienes\, especially with colleagues in Sw eden\, and the synthesis of target compounds as potential drugs for treati ng cancer and a rare\, inherited disease.
\n\n
Abstract with refer ences for download here
\nMore information about the Tage Erlander professor 2011
DTSTART;TZID=Europe/Stockholm:20111214T130000 DTEND;TZID=Europe/Stockholm:20111214T140000 SUMMARY:KBC Lecture - Paul Helquist: From Simple Diene Chemistry to Therapi es for Rare and Neglected Diseases URL:http://www.ucmr.umu.se/about-ucmr/events/162-ucmr-calendar/164-seminar/ 152-kbc-lecture-paul-helquist-from-simple-diene-chemistry-to-therapies-for -rare-and-neglected-diseases.html X-ALT-DESC;FMTTYPE=TEXT/HTML:KBC Lecture
\nTage-Erlander Professor 2011
\n\n
Paul Helquist
\nDepartment of Chemistry & Biochemistry\, University of Notre Dame\, Notre Dame\, Indi ana
\n\n
Title:
\nFrom Simple Diene Chemistry t o Therapies for Rare and Neglected Diseases
\n\n
Abs tract
\nIn a joint set of ventures\, the Wiest and Helquist laborato ries at Notre Dame\, specializing in computational chemistry and drug synt hesis\, respectively\, are supported by various funding mechanisms to reac h out to investigators in other fields and at many institutions to form mu lti-disciplinary collaborative teams for the purpose of drug development. Most often\, the external collaborators are at medical schools or other bi omedical institutions and have major strengths in biological or clinical s tudies but do not have the chemistry expertise required for drug developme nt. These collaborators have often identified a potential therapeutic prot ein target from cellular studies\, or they have conducted compound screeni ngs to identify initial hits. The next logical steps in these investigatio ns are the design of protein binders or hit optimization\, requiring the c omputational and synthetic chemistry input of our laboratories. The result ing compounds are provided back to the external collaborators and other ap propriate parties for more extensive biological studies. Over the past few years\, these collaborative ties have been established with many investig ators at Cornell University Weill College of Medicine\, Tufts University M edical School\, Columbia University College of Physicians and Surgeons\, W ashington University School of Medicine\, University of Texas Southwestern Medical Center\, Broad Institute\, Dana-Farber Cancer Institute\, Purdue University\, State University of New York at Albany\, and Biological Scien ces at Notre Dame.
\nThis presentation will place emphasis on the hi story of our development of synthetic methods for dienes\, especially with colleagues in Sweden\, and the synthesis of target compounds as potential drugs for treating cancer and a rare\, inherited disease.
\n\n \n END:VEVENT END:VCALENDAR